Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
Posted on 2020-07-23 - 04:49
Abstract Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Xiao, Kun; Hou, Fei; Huang, Xiuyu; Li, Binbin; Qian, Zhi Rong; Xie, Lixin (2020). Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.5070849.v1
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (6)
KX
Kun Xiao
FH
Fei Hou
XH
Xiuyu Huang
BL
Binbin Li
ZQ
Zhi Rong Qian
LX
Lixin Xie